Literature DB >> 8701376

Intravenous amiodarone for therapy of atrial fibrillation and flutter in critically ill patients with severely depressed left ventricular function.

A Kumar1.   

Abstract

A retrospective review was done to determine the efficacy and hemodynamic effects of slow intravenous amiodarone administration on invasively monitored patients with acute onset of atrial fibrillation or atrial flutter and left ventricular ejection fractions < 15%. Eight patients met predefined inclusion criteria. All received 300 mg amiodarone intravenously over 1 hour. Seven reverted to sinus rhythm within 1 hour, with return of most hemodynamic variables to baseline. Before reversion, each patient experienced a beneficial slowing of heart rate (mean, 28%) resulting in significant improvement of stroke volume index (mean, 49%) and left ventricular stroke work index (mean, 61%). No patient had hemodynamic deterioration attributable to amiodarone infusion. Slow intravenous infusion of amiodarone appears to be an effective and hemodynamically well-tolerated therapy for atrial fibrillation and atrial flutter in critically ill patients with marked depression of left ventricular systolic function.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8701376     DOI: 10.1097/00007611-199608000-00005

Source DB:  PubMed          Journal:  South Med J        ISSN: 0038-4348            Impact factor:   0.954


  9 in total

1.  Efficacy and safety of intravenous amiodarone in recent-onset atrial fibrillation: experience in patients admitted to a general internal medicine department.

Authors:  Y Kreiss; Y Sidi; H Gur
Journal:  Postgrad Med J       Date:  1999-05       Impact factor: 2.401

2.  Rate and rhythm are important in critically ill patients.

Authors:  Egbert Pravinkumar
Journal:  BMJ       Date:  2003-10-18

Review 3.  Acute management of atrial fibrillation with acute haemodynamic instability and in the postoperative setting.

Authors:  C J Mann; S Kendall; G Y H Lip
Journal:  Heart       Date:  2006-09-04       Impact factor: 5.994

4.  Intravenous amiodarone for treating acute life threatening arrhythmias.

Authors:  S R Votey; M E Herbert
Journal:  West J Med       Date:  1998-03

Review 5.  2014 AATS guidelines for the prevention and management of perioperative atrial fibrillation and flutter for thoracic surgical procedures.

Authors:  Gyorgy Frendl; Alissa C Sodickson; Mina K Chung; Albert L Waldo; Bernard J Gersh; James E Tisdale; Hugh Calkins; Sary Aranki; Tsuyoshi Kaneko; Stephen Cassivi; Sidney C Smith; Dawood Darbar; Jon O Wee; Thomas K Waddell; David Amar; Dale Adler
Journal:  J Thorac Cardiovasc Surg       Date:  2014-06-30       Impact factor: 5.209

6.  High-dosage continuous amiodarone therapy to treat new-onset supraventricular tachyarrhythmias in surgical intensive care patients: an observational study.

Authors:  Andreas J Mayr; Martin W Dünser; Nicole Ritsch; Werner Pajk; Barbara Friesenecker; Hans Knotzer; Hanno Ulmer; Volker Wenzel; Walter R Hasibeder
Journal:  Wien Klin Wochenschr       Date:  2004-05-31       Impact factor: 1.704

7.  Modeling of Amiodarone Effect on Heart Rate Control in Critically Ill Patients with Atrial Tachyarrhythmias.

Authors:  Joe-Elie Salem; Maria El-Aissaoui; Margaux Alazard; Jean-Sébastien Hulot; Nadia Aissaoui; Jean-Yves Le-Heuzey; Christian Funck-Brentano; Christophe Faisy; Saik Urien
Journal:  Clin Pharmacokinet       Date:  2016-08       Impact factor: 6.447

Review 8.  Clinical review: treatment of new-onset atrial fibrillation in medical intensive care patients--a clinical framework.

Authors:  Mengalvio E Sleeswijk; Trudeke Van Noord; Jaap E Tulleken; Jack J M Ligtenberg; Armand R J Girbes; Jan G Zijlstra
Journal:  Crit Care       Date:  2007       Impact factor: 9.097

9.  Variable use of amiodarone is associated with a greater risk of recurrence of atrial fibrillation in the critically ill.

Authors:  Goran Mitrić; Andrew Udy; Hiran Bandeshe; Pierre Clement; Rob Boots
Journal:  Crit Care       Date:  2016-04-02       Impact factor: 9.097

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.